IRadimed Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRMD research report →
Range $120 – $120
Price Chart
About the company
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U. S.
- CEO
- Roger E. Susi
- IPO
- 2014
- Employees
- 166
- HQ
- Orlando, FL, US
Get TickerSpark's AI analysis on IRMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.04B
- P/E
- 44.15
- Fwd P/E
- 38.64
- PEG
- 3.35
- P/S
- 11.95
- P/B
- 10.02
- EV/EBITDA
- 31.50
- Div Yield
- 1.56%
- Gross Margin
- 75.51%
- Op Margin
- 32.30%
- Net Margin
- 26.85%
- ROE
- 23.90%
- ROIC
- 20.09%
Latest fiscal year · YoY change
- Revenue
- $83.81M+14.4%
- Gross Profit
- $64.32M+14.2%
- Op Income
- $26.15M
- Net Income
- $22.48M+16.9%
- EPS
- $1.77+16.4%
- OCF Growth
- -2.6%
- FCF Growth
- -2.5%
- 52W High
- $107.90
- 52W Low
- $76.35
- 50D MA
- $85.27
- 200D MA
- $91.45
- Beta
- 0.91
- RSI (14)
- 40
- Avg Volume
- 120.50K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IRadimed delivered record Q3 revenue and bookings, with the new 3870 pump driving growth, improving margins, and setting up a strong Q4, though management trimmed full-year revenue guidance to reflect a cautious ramp.· October 30, 2026
- Record Q3 revenue of $24.2 million, up 14% year over year and 18% sequentially, with GAAP EPS of $0.51 and non-GAAP EPS of $0.55.
- The 3870 MR IV pump ramp is the main growth engine: management said Q3 output was over 400 systems, with over 300 shipped and Q4 expected to grow pump output another 50-plus percent.
- Gross margin improved sequentially to 76% as production efficiencies emerged, and management said margins should keep improving as volumes rise.
- Monitor sales remained strong, with another record quarter for bookings, helping ease earlier concerns that the new pump launch would distract from the monitor business.
- Full-year 2026 guidance was narrowed to revenue of $91.7 million to $93.2 million, reflecting a more cautious ramp despite strong demand and backlog.
For Q3 2026, revenue was a record $24.2 million, up 14% from $21.2 million a year ago and up 18% from $20.5 million in Q2. GAAP diluted EPS was $0.51, up from $0.43, and non-GAAP diluted EPS was $0.55, up from $0.47. Gross profit was $18.5 million with a 76% margin, compared with $16.5 million and 78% in Q3 2025; sequentially, management said gross margin improved 2 points from 74% in Q2. For the first nine months, revenue was $66.6 million, up 9%, and non-GAAP diluted EPS was $1.50, up 8%. For Q4, management guided to revenue of $25 million to $26.5 million, GAAP EPS of $0.53 to $0.57, and non-GAAP EPS of $0.57 to $0.61. Full-year 2026 guidance was updated to revenue of $91.7 million to $93.2 million, GAAP EPS of $1.90 to $1.94, and non-GAAP EPS of $2.06 to $2.10.
Roger Susi said the 3870 pump launch is exceeding expectations and described the quarter as evidence that the company has successfully executed a difficult production ramp. He emphasized record bookings for both the 3880 monitor and 3870 pump, a comfortable Q4 backlog, and continued customer acceptance of the new system. His tone was upbeat and confident, while also noting that management is being careful not to push the ramp so hard that quality slips.
John Glenn highlighted record quarterly revenue of $24.2 million, gross profit of $18.5 million, and operating income of $8.1 million, along with cash and cash equivalents of $63.3 million at quarter end. He said gross margin was 76% in Q3 and should improve further in Q4 as 3870 volumes increase, while noting the year-over-year margin decline was due to remaining production inefficiencies on the new pump. He also noted cash flow from operations of $7 million, non-GAAP free cash flow of $6.8 million, capital expenditures of $0.2 million for the quarter, and a quarterly dividend of $0.20 per share.
Analysts focused on why full-year revenue guidance came down even though bookings hit records, and management said the issue was the difficulty of ramping 3870 production fast enough without risking quality. Questions also centered on disposables, 2027 growth, greenfield demand, monitor momentum, and gross margin. Management said disposable usage from the new pump is still too early to show up because in-servicing takes 6 to 8 weeks, but it should begin to contribute later in Q4 and into 2027. They also said monitor sales remain healthy, with recent enhancements to remote capabilities helping sales, and that 2027 should still see double-digit growth even if manufacturing ramp rates moderate.
The call showed strong demand for the new 3870 pump, with record bookings, a large backlog, and management saying the product is gaining traction faster than expected in both replacement and greenfield accounts. Margin leverage is starting to show through, and management believes gross margin can move back toward historical 77% to 78% levels as volumes build. The company also reinforced confidence in continued monitor growth and in a path toward an annualized revenue run rate above $100 million.
Management cut the top end of full-year revenue guidance because pump production is still constrained by execution risk and the need to protect quality during the ramp. Disposable revenue has not yet benefited meaningfully from the new installed base because customers are only beginning to use the 3870 after in-servicing. Gross margin is improving, but management said international mix can still pressure margins and the new pump still carries some manufacturing inefficiency.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 65.1%
- Shares Outstanding
- 12.79M
- Float Shares
- 8.33M
of shares held by institutions
218 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 967.83K | ▲ 38 |
| Vanguard Group Inc | 560.05K | ▼ 6.46K |
| Kayne Anderson Rudnick Investment Management LLC | 396.98K | ▲ 47.67K |
| Copeland Capital Management, LLC | 382.01K | ▼ 9.85K |
| Vanguard Capital Management LLC | 364.94K | ▲ 6.32K |
| Renaissance Technologies LLC | 350.61K | ▼ 43.80K |
| T. Rowe Price Investment Management, Inc. | 318.68K | ▲ 61.98K |
| Geode Capital Management, LLC | 296.23K | ▲ 6.12K |
| State Street Corp | 237.78K | ▲ 16.27K |
| Dimensional Fund Advisors LP | 230.98K | ▲ 1.64K |
| Goldman Sachs Group Inc | 214.15K | ▲ 16.21K |
| Two Sigma Investments, LP | 182.89K | ▲ 17.23K |
Held by 219 ETFs
Biggest fund positions in IRMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | KIANI JOE E | other | 698 |
| Sep 23, 26 | KIANI JOE E | other | 698 |
| Sep 3, 26 | ALLEN MONTY K | sell | 1,014 |
| Sep 3, 26 | ALLEN MONTY K | sell | 405 |
| Jun 20, 26 | GLENN JOHN | other | 5,796 |
| Jun 20, 26 | GLENN JOHN | other | 2,319 |
| Jun 20, 26 | GLENN JOHN | other | 5,796 |
| Jun 4, 26 | Scharen-Guivel Hilda Frederique | sell | 1,766 |
| Jun 4, 26 | Scharen-Guivel Hilda Frederique | sell | 1,234 |
| Jun 1, 26 | Susi Roger E. | sell | 400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRMD coverage
Recent articles, reports, and earnings notes.
No research on IRMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRMD report →What iRadimed (IRMD) Said on Its Q3 Earnings Call
marketbeat.com · Oct 30
IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 30
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
globenewswire.com · Oct 30
Riverwater Small Cap Strategy Q3 2026 Portfolio Update
seekingalpha.com · Oct 28
iRadimed (IRMD) Expected to Post Earnings on Friday
defenseworld.net · Oct 26
IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
globenewswire.com · Oct 23
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
globenewswire.com · Sep 23
Head-To-Head Contrast: iRadimed (NASDAQ:IRMD) & Medline (NASDAQ:MDLN)
defenseworld.net · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.